M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
76 deals · US$92bndisclosed · Pharma · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Jun 2025 | Felix Pharmaceuticals Pvt | – | Advent International | Stake | Announced | – | Animal Health+2 | A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side) |
| Jul 2025 | Altanine | – | Polomar Health Services | Merger | Pending | – | Healthcare+1 | |
| Sep 2025 | Zentiva | Advent International | GTCR | Acquisition | Announced | – | Pharma+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Dec 2025 | MindWave Innovations | – | Apimeds Pharmaceuticals US | Merger | Completed | – | Biotech+1 | Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side) |
| Dec 2025 | Amicus Therapeutics | – | BioMarin | Acquisition | Announced | 4,800.0 | Biotech+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Dec 2025 | Dynavax Technologies | – | Sanofi | Acquisition | Announced | 2,200.0 | Biotech+1 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side) |
| 2026 | Istituto Biochimico Italiano Giovanni Lorenzini (IBI Lorenzini) | – | ACS Dobfar | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Lincoln International (sell-side) |
| 2026 | Egetis | – | ANI Pharmaceuticals | Acquisition | Announced | 560.0 | Pharma+1 | Centerview Partners (sell-side) |
| Jan 2026 | Biogaran | Servier | BC Partners | Acquisition | Announced | – | Pharma | Lazard |
| Jan 2026 | Wonderbelly | – | Procter & Gamble | Acquisition | Completed | – | Consumer Health+1 | Perella Weinberg Partners (sell-side) |
| Jan 2026 | Lantheus SPECT business | Lantheus | SHINE Technologies | Asset sale | Announced | – | Pharma+2 | Solomon Partners (sell-side) |
| Jan 2026 | Nivagen Pharmaceuticals | – | PAI Pharma | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side) |
| Jan 2026 | PTC Therapeutics' remaining royalty on Roche's Evrysdi | PTC Therapeutics | Royalty Pharma | Asset sale | Announced | 240.0 | Specialty finance and leasing+2 | Goodwin (buy-side) |
| Jan 2026 | Ventyx Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 1,200.0 | Biotech+2 | Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side) |
| Jan 2026 | Radius Health | Patient Square Capital | B-FLEXION Life Sciences | Acquisition | Announced | – | Pharma | Kirkland & Ellis (sell-side)Centerview Partners (sell-side) |
| Jan 2026 | TerSera Infusion Specialty Therapies Business Unit (IST) | TerSera Therapeutics | ESTEVE | Asset sale | Pending | – | Pharma | Kirkland & Ellis (sell-side)Leerink Partners (sell-side)Perella Weinberg Partners (buy-side)Arnold & Porter (buy-side) |
| Feb 2026 | Apex Healthcare Berhad | – | Quadria Capital-led consortium | Acquisition | Announced | – | Pharma+1 | Latham & Watkins (buy-side) |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,400.0 | Biotech+1 | Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | Avadel Pharmaceuticals | – | Alkermes | Scheme | Completed | – | Pharma+1 | Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side) |
| Feb 2026 | AiCuris Anti-infective Cures AG | – | Veloxis Pharmaceuticals | Acquisition | Announced | 913.0 | Pharma+1 | Gibson Dunn (sell-side)Freshfields (buy-side) |
| Mar 2026 | Transcend Therapeutics | – | Otsuka | Acquisition | Announced | 700.0 | Biotech+2 | Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side) |
| Mar 2026 | Paratek Pharmaceuticals | – | – | Merger | Completed | – | Pharma | Skadden, Arps, Slate, Meagher & Flom |
| Mar 2026 | Manufacturing facility in Phoenix, AZ | Bristol Myers Squibb | Rovi | Asset sale | Completed | – | Pharmaceutical Manufacturing+1 | William Blair |
| Mar 2026 | Corstasis Therapeutics | – | Esperion Therapeutics | Acquisition | Completed | 75.0 | Pharma+1 | PJT Partners (sell-side)Arnold & Porter (sell-side)Jefferies (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Novartis India | Novartis AG | WaveRise Investments | Acquisition | Announced | – | Pharma | Freshfields (sell-side) |
| Mar 2026 | Day One Biopharmaceuticals | – | Servier | Acquisition | Pending | 2,500.0 | Biotech+2 | Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side) |
| Mar 2026 | AZSTARYS business | Corium Therapeutics Holdings | Collegium Pharmaceutical | Asset sale | Pending | 650.0 | Pharma | Centerview Partners (sell-side)Sullivan & Cromwell (sell-side)Leerink Partners (buy-side)Goodwin (buy-side) |
| Mar 2026 | AnaptysBio outstanding common stock | – | AnaptysBio | Buy-back | Announced | 100.0 | Biotech+1 | Piper Sandler (buy-side) |
| Mar 2026 | Kezar Life Sciences | – | Aurinia Pharmaceuticals | Acquisition | Announced | 51.5 | Biotech+1 | TD Securities (sell-side)Cooley (sell-side) |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side) |
| Mar 2026 | Centessa Pharmaceuticals | – | Eli Lilly and Company | Scheme | Pending | 6,300.0 | Biotech+1 | Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Cumberland U.S. branded businesses | Cumberland Pharmaceuticals | Apotex | Asset sale | Announced | – | Pharma | Kirkland & Ellis (buy-side) |
| Apr 2026 | Modeyso commercial sales royalties | Former Oncoceutics Inc. securityholders | HealthCare Royalty | Asset sale | Announced | – | Specialty finance and leasing+3 | Latham & Watkins (sell-side) |
| Apr 2026 | Exclusive global rights to TAK-063 (balipodect) | Takeda Pharmaceutical Co. | Axsome Therapeutics | Asset sale | Completed | – | Pharma+1 | Sidley Austin (buy-side) |
| Apr 2026 | Soleno Therapeutics | – | Neurocrine Biosciences | Acquisition | Completed | 2,900.0 | Biotech+2 | Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side) |
| Apr 2026 | Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Completed | 35.0 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side) |
| Apr 2026 | Worldwide rights to Kenalog | Bristol-Myers Squibb | Subsidiary of Piramal Pharma | Asset sale | Announced | 35.0 | Pharma | Goodwin (buy-side) |
| Apr 2026 | Assertio Holdings | – | Zydus Worldwide DMCC | Acquisition | Announced | 166.4 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side)Longacre Square Partners (sell-side)Paul, Weiss (buy-side) |
| Apr 2026 | US sales and distribution rights for seven Assertio branded products | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Announced | – | Pharma | Gibson Dunn (sell-side) |
| Apr 2026 | Neurona Therapeutics | – | UCB | Acquisition | Announced | 650.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Apr 2026 | Kashiv BioSciences | – | Amneal Pharmaceuticals | Acquisition | Completed | 375.0 | Biotech+2 | J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side) |
| Apr 2026 | Cumberland FDA-approved commercial products and related assets | Cumberland Pharmaceuticals | Nuvo Pharmaceuticals (Ireland) DAC | Asset sale | Pending | 100.0 | Pharma | VelocityHealth Securities (sell-side)Baker Donelson (sell-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Organon & Co. | – | Sun Pharmaceutical Industries | Acquisition | Announced | 11,750.0 | Pharma | Morgan Stanley (sell-side)Goldman Sachs (sell-side)Sullivan & Cromwell (sell-side)Cyril Amarchand Mangaldas (sell-side)J.P. Morgan (buy-side)Jefferies (buy-side)White & Case (buy-side)AZB & Partners (buy-side) |
| Apr 2026 | KalVista Pharmaceuticals | – | Chiesi Group | Acquisition | Completed | 1,900.0 | Pharma+2 | Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side) |
| Apr 2026 | Shionogi-Apnimed Sleep Science | Apnimed | Shionogi & Co. | Acquisition | Announced | 100.0 | Pharma+1 | Goodwin (sell-side) |
| Apr 2026 | Emalex Biosciences | – | Teva Pharmaceuticals | Acquisition | Announced | 700.0 | Pharma+1 | Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side) |
| May 2026 | CVC and GBL-led Recordati acquisition consortium | – | CPP Investments | Stake | Announced | – | Pharma | Kirkland & Ellis (buy-side) |
| May 2026 | Recordati S.p.A. | – | CVC GBL | Acquisition | Announced | 12,516.9 | Pharma | Latham & Watkins (buy-side)Jefferies (buy-side) |
| May 2026 | Esperion Therapeutics | – | ARCHIMED | Acquisition | Pending | 1,100.0 | Pharma+1 | Latham & WatkinsCenterview Partners (sell-side)Goodwin (sell-side)Moelis & Company (buy-side)Sidley Austin (buy-side) |
| May 2026 | Catalyst Pharmaceuticals | – | Angelini Pharma S.p.A. | Acquisition | Pending | 4,100.0 | Pharma+1 | J.P. Morgan (sell-side)Kirkland & Ellis (sell-side)Akerman (sell-side)Centerview Partners (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Hogan Lovells Cadwalader (buy-side)Gatti Pavesi Bianchi Ludovici (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.